The Trump administration is reportedly considering a plan that would bypass normal regulatory procedures to fast-track an experimental coronavirus vaccine developed in the United Kingdom so that it can be used in the United States ahead of the November presidential election, according to the Financial Times.
One option that is reportedly under consideration involves issuing an emergency use authorization, like the one that was announced Sunday for plasma treatment, to a vaccine being developed by AstraZeneca and Oxford University.
That authorization would be on the back of a small U.K. study that, even if successful, would fall far short of the normal requirements for the approval of a vaccine. Top administration officials told congressional leaders last month they were likely to award emergency approval for a vaccine before the end of Phase 3 clinical trials in the United States.
The New York Times also reported on this July 30 meeting in which Treasury Secretary Steven Mnuchin and the White House chief of staff, Mark Meadows reportedly revealed the plan to congressional leaders, including House Speaker Nancy Pelosi and Sen. Chuck Schumer.
During the meeting, the administration officials said that the AstraZeneca vaccine that is being developed with Oxford University was the most likely candidate, according to the Times. Pelosi reportedly warned there should be “no cutting corners” in getting a vaccine approved, reports the FT. Administration officials disputed the accounts of what was said at the meeting with spokesmen for Meadows and Mnuchin both claiming neither of them discussed the prospects for the AstraZeneca vaccine.